Esafosfina 5 g/50 ml.

Description

Esafosfina 5 g/50 ml. Solution

Composition

The primary active substance in Esafosfina is Sodium Phosphate Monobasic. Each 50 ml of the solution contains 5 g of Sodium Phosphate Monobasic. The other components include water for injections and sodium hydroxide for pH adjustment.

Description

Esafosfina 5 g/50 ml. is a clear, colorless, sterile solution for intravenous administration. Its main purpose is to replenish the phosphate in the body, particularly in conditions that lead to hypophosphatemia (low phosphate levels). The medication is prepared under sterile conditions and is used under medical supervision.

Indication

Esafosfina is indicated for the treatment of hypophosphatemia, which may occur in various clinical situations, including alcohol withdrawal, diabetic ketoacidosis, and in patients on parenteral nutrition. It is also used in conditions of increased phosphate utilization such as in rapidly growing children, pregnant women, and during lactation. In addition, it is indicated during total parenteral nutrition, for phosphate supplementation.

Administration and Dosage

This medication is to be administered intravenously, under the supervision of a healthcare professional. The dosage and duration of the treatment will depend on the patient’s age, weight, renal function, as well as the severity of the hypophosphatemia. The healthcare professional will monitor serum phosphate levels regularly during the treatment to ensure that the desired levels are being maintained.

Contraindications

Esafosfina is contraindicated in patients with hyperphosphatemia (high phosphate levels), severe renal insufficiency, and in conditions where there is a risk of hyperphosphatemia, such as Addison’s disease, acute nephritis, and severe liver disease. It should not be used in patients who are hypersensitive to any of the ingredients in the solution.

Precautions

Before starting treatment with Esafosfina, the healthcare professional should assess the patient’s renal function, as well as their calcium and phosphate levels. During treatment, they should monitor these parameters regularly. In case of overcorrection of hypophosphatemia or signs of hyperphosphatemia, the treatment should be adjusted or discontinued. The solution should be used with caution in patients with cardiac disease, as rapid correction of hypophosphatemia can lead to hyperphosphatemia and subsequent calcium-phosphate precipitation in the body, which can cause organ damage.

Interactions

Esafosfina might interact with certain medications, such as digoxin, antacids containing aluminum, calcium or magnesium, potassium-sparing diuretics, or vitamin D supplements. The healthcare professional should be aware of all the medications the patient is taking before starting the treatment with Esafosfina.

Side Effects

Like all medications, Esafosfina can cause side effects, although not everybody gets them. Possible side effects include hypocalcemia (low calcium levels), hyperphosphatemia, hypotension (low blood pressure), tachycardia (rapid heart rate), nausea, vomiting, diarrhea, and localized reactions at the injection site such as redness, swelling, pain, or irritation. In case of any side effects, the patient should inform their healthcare professional immediately.

Storage

Esafosfina should be stored at room temperature, away from heat and direct sunlight. It should not be frozen. Keep it out of the reach of children and pets.